Brown Graham K, Finlay Jessica R, Straw Rodney C, Ziea Joy Y, Leung Becky, O'Connell Kathleen, Thomson Maurine J, Campbell Justine E, Jones Pamela D, Reddell Paul
QBiotics Group Limited, Yungaburra, QLD, Australia.
Perth Veterinary Specialists, Osborne Park, WA, Australia.
Front Vet Sci. 2022 Oct 26;9:1003165. doi: 10.3389/fvets.2022.1003165. eCollection 2022.
Mast cell tumours (MCTs) are common canine skin neoplasia. While they generally occur as single tumours, multiple synchronous MCTs (msMCTs) of /non-metastatic origin are reported in a proportion of the patient population. Where there is no evidence of metastasis or lymphatic spread, MCTs are effectively controlled by surgery and other local therapies. However, treatment of msMCTs can be more challenging, especially when they occur in surgically difficult locations. Here, we report the use of tigilanol tiglate, a novel small molecule registered as a veterinary pharmaceutical for the local treatment of non-metastatic MCTs, in the treatment of patients with msMCTs presenting at three Australian specialist referral centres. We also present a meta-analysis of the literature to provide a better understanding of the prevalence of canine msMCTs. Notably, nine patients with a total of 32 MCTs were treated during the study. A complete response was recorded in 26 (81%) of the individual MCTs on Day 28 after a single tigilanol tiglate injection. Of the 6 initially non-responsive MCTs, one achieved a complete response after a further tigilanol tiglate treatment. A complete response was reported at 6 months in all 22 of the tumours that were evaluable and that had recorded a complete response at Day 84. For the literature meta-analysis, 22 studies were found with prevalence estimates of msMCTs ranging from 3 to 40%; when combined, these studies yielded 3,745 patients with a prevalence of 13% (95% CI 10; 16). Overall, the results demonstrate the utility of intratumoural tigilanol tiglate as an option for the treatment of multiple MCTs where multiple surgical resections would have been required.
肥大细胞瘤（MCTs）是常见的犬类皮肤肿瘤。虽然它们通常以单个肿瘤的形式出现，但有一定比例的患者群体中会出现非转移性起源的多发性同步肥大细胞瘤（msMCTs）。在没有转移或淋巴扩散证据的情况下，肥大细胞瘤可通过手术和其他局部治疗得到有效控制。然而，msMCTs的治疗可能更具挑战性，尤其是当它们出现在手术难度较大的部位时。在此，我们报告了替吉奥硝唑醇（tigilanol tiglate）的使用情况，这是一种注册为兽用药物的新型小分子，用于局部治疗非转移性肥大细胞瘤，治疗了在澳大利亚三个专科转诊中心就诊的msMCTs患者。我们还对文献进行了荟萃分析，以更好地了解犬类msMCTs的患病率。值得注意的是，在研究期间共治疗了9例患者，其共有32个肥大细胞瘤。单次注射替吉奥硝唑醇后第28天，26个（81%）单个肥大细胞瘤记录为完全缓解。最初6个无反应的肥大细胞瘤中，有1个在进一步接受替吉奥硝唑醇治疗后达到完全缓解。在所有22个可评估且在第84天记录为完全缓解的肿瘤中，6个月时均报告为完全缓解。对于文献荟萃分析，发现22项研究中msMCTs的患病率估计范围为3%至40%；综合这些研究，共有3745例患者，患病率为13%（95%CI 10；16）。总体而言，结果表明肿瘤内注射替吉奥硝唑醇可作为一种治疗选择，用于治疗需要进行多次手术切除的多发性肥大细胞瘤。
